After years of deep freeze, signs of life exist in the biopharma IPO market. Sure, the number of IPOs this year (13) was fewer than 2010 (16). Of the 26 launched since 2010, two-thirds now trade at a loss to investors. But some signs of hope exist judging from a smaller percentage of firms discounting on their IPOs this year compared to last year as well as their post-IPO performance. Aveo Pharmaceuticals, which went public in March 2010, has seen its share price zoom 84% since it went public. Of the two most recent biopharma companies to go public, one is trading above its IPO price, while another is unchanged. What will the IPO market look like next year?

Poll Question:
Do you think the IPO window will swing open wider in 2012?




Previous articleTranslational Medicine Center for Infectious Diseases Set Up in Shanghai
Next articleAMT Raises €2.5M but Says Future Still Hangs in the Balance